Cargando…
Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Real-world evidence (RWE) has garnered great interest to support registration of new therapies and label expansions by the United States Food and Drug Administration (FDA). Currently, practical insights on the design and analysis of regulatory-grade RWE are lacking. This study aimed to analyze attri...
Autores principales: | Arondekar, Bhakti, Duh, Mei Sheng, Bhak, Rachel H., DerSarkissian, Maral, Huynh, Lynn, Wang, Kelsey, Wojciehowski, John, Wu, Melody, Wornson, Bryon, Niyazov, Alexander, Demetri, George D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401526/ https://www.ncbi.nlm.nih.gov/pubmed/34667027 http://dx.doi.org/10.1158/1078-0432.CCR-21-2639 |
Ejemplares similares
-
2512. Decreasing Adherence to Antiretroviral Therapy over 4 Years of Follow-up in a Commercially-Insured Population of Patients with HIV
por: Priest, Julie, et al.
Publicado: (2019) -
RE: Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
por: Zou, Denise, et al.
Publicado: (2021) -
Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018) -
Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021) -
The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications
por: Purpura, Christina A., et al.
Publicado: (2021)